when a better treatment is just not good enough
Progress in the battle against HIV/AIDS only happens through
years of scrupulous research and experimentation; think of this as the process
for “moving the needle” forward. HIV Cure Foundation matches philanthropic
contributions to fund innovations that build on decades of progress towards
ending the HIV/AIDS epidemic. Just as yesterday’s clinical trials improve the
lives of people currently living with HIV/AIDS, today’s hard work will one day
make HIV/AIDS a relic of history... HIV Cure Foundation’s mission is to ensure
progress continues.
HIV Cure Foundation (HCF) was founded by a group of passionate
individuals determined to find a cure for the disease that has plagued the
world since 1981. HCF was created for the individuals who need #theHIVCure more
than anything. HCF filed for a 501(c)3 determination from the IRS on November
2, 2020.
Moving the needle
of progress requires identifying and funding innovative,
science-based research. HIV Cure Foundation is committed to providing the funds
for clinical research that will provide relief from taking daily medications,
long term side effects and the stigma of HIV/AIDS.
As of March 2021, HIV Cure Foundation announced the financial
support of their first human clinical trial: “Phase 1 Study to Evaluate the Safety of Genetically Modified, Autologous T Cells in Participants With HIV That is Well-Controlled on Antiretroviral Therapy” This research is one of many crucial avenues
of experimentation in the ongoing fight against HIV/AIDS. Should this research
prove effective, it would provide clinical participants a functional cure,
meaning the
virus is not completely eliminated by the body's immune system but can be
controlled without medication.
After FDA approval, people living with HIV would no longer require their
antiretroviral therapy, no longer be able to progress to AIDs or transmit the
virus to others.
Maryland-based, American Gene Technologies is a clinical-stage
gene and cell therapy company that has developed AGT103-T, a single dose,
autologous cell therapy intended to cure HIV.
Greenlighted by the FDA, human clinical trials are currently
underway in Washington, DC at Georgetown University and Washington Health
Institute. This study is registered with The NIH National Library of Medicine Clinical Trials Registry.
Your donation in any amount will help
make life-changing research possible.
#theHIVCure is on the horizon, we invite you to give generously today:
• any portion of one patient’s clinical trial ($500...$2,500...$25,000...any amount)
• an entire patient ($150,000)
• an entire trial! ($1mil+)